Would you like to auto play audio?
NO
YES
References
Prepare for PFHO
and target treating DED in dual action mode
PFHO Mode of Action
Explore Universes
Thought Leaders
Let's Know What Our Researchers Talk About Tear Film
Dr Farrell C Tyson
MD
Key Words
Dry Eye
Dry Eye Disease
Lipid Layer
Aqueous Layer
Mucin Layer
Epithelial Layer
Redness Eye
Related Videos
About the
Supramolecular Self-assembly
Learn how 1-perflourohexyloctane forms monolayers
Severity of the Dry Eye Disease
Click below buttons to see the severity of the Dry Eye Disease in different grades
Grade 0
Grade 1
Grade 2
Grade 3
Grade 4
Grade 5
Severity: Normal
Numerous oval shaped goblet cells
Tightly packed non-secretary epithelial cells
Severity: Mild
Moderate number of goblet cells
Slightly separated non-secretary epithelial cells
Severity: Moderate
A few goblet cells
Moderately separated non-secretary epithelial cells
Severity: High
Very small number of goblet cells
More separated & sometimes binucleated non-secretary epithelial cells
Severity: Severe
Goblet cells have disappeared
Non-secretary epithelial cells were isolated, and their cytoplasm keratinized
Severity: Severe+
Goblet cells have disappeared
Tightly packed Non-Secretary epithelial Cells
How Meibo Works?
Chapter 1
Chapter 2
Chapter 3
Chapter 1
Introduction to the Dry Eye Disease
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.
Chapter 2
Introduction to the Dry Eye Disease
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.
Chapter 3
Introduction to the Dry Eye Disease
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.
Severity of DED
How Meibo Works
Safety
Efficacy
Thought Leaders
About Meibo
Explore Tear Film Universe
Lipid Layer
The outer layer that helps reduce evaporation of natural tears
Aqueous Layer
The middle layer that washes away particles and prevents infection
Mucin Layer
The inner layer that helps the eye remain lubricated
MEIBO has unique physiochemical properties
Parameters MEIBO Formulations Containing Water
Drop Size
  • 11 μL
  • Does not oversaturate ocular surface
    		•
  • ~ 35 to 50 μL
    		•
    Drug Residence Time
  • Remains in tears for upto 6 hours(PK rabbit study)
    		•
  • Breif, 3 to 5 minutes
    		•
    Spreading
  • Low surface tension
  • Rapid spreading
  • Film-forming
    		•
  • High surface tension
  • Hinders spreading
    		•
    Other features
  • Water free - no preservatives
  • Low refractive index - minimal vision blurring
  • Can carry 10x more oxygen than water
    		•
  • Usually preserved
  • Blurring with emulsions
  • Blurring with suspensions
    		•
    MEIBO (100% perfluorohexyloctane)
    Highly Asymmetric Structure
    Amphiphilic-aerophilic fluorinated segment and lipophilic hydrocarbon segment
    Single-ingredient formulation
    Water Free
    Preservative Free
    Steroid Free
    Perfluorohexyloctane
    INDICATION
    MIEBO™ (perfluorohexyloctane ophthalmic solution) is a semifluorinated alkane indicated for the treatment of the signs and symptoms of dry eye disease.
    IMPORTANT SAFETY INFORMATION
    MIEBO should not be administered while wearing contact lenses. Contact lenses should be removed before use and for at least 30 minutes after administration of MIEBO
    Instruct patients to instill one drop of MIEBO into each eye four times daily
    The safety and efficacy in pediatric patients below the age of 18 have not been established
    The most common ocular adverse reaction was blurred vision (1% to 3% of patients reported blurred vision and conjunctival redness)
    You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1800FDA10
    A tolerability profile you've been looking for
    In 2 pivotal clinical studies with > 600 patients treated with MIEBO
    0
    No incidences of serious ocular adverse events (AEs)2,3
    Most AEs were considered mild
    0.2%
    Low discontinuation rate due to AEs2-4
    Discontinuation rate for MIEBO was comparable to control (pooled: 0.2% vs 0.5%; GOBI 0.3% vs 1.0%; MOJAVE 0% vs 0%
    0.2%
    Low discontinuation rate due to AEs2-4
    Discontinuation rate for MIEBO was comparable to control (pooled: 0.2% vs 0.5%; GOBI 0.3% vs 1.0%; MOJAVE 0% vs 0%
    0.5%
    Low rate of burning or stinging2-4
    The pooled incidence of instillation site pain, such as burning or stinging, was 0.5% GOBI 1.0%; MOJAVE 0%
    INDICATION
    MIEBO™ (perfluorohexyloctane ophthalmic solution) is a semifluorinated alkane indicated for the treatment of the signs and symptoms of dry eye disease.
    IMPORTANT SAFETY INFORMATION
    MIEBO should not be administered while wearing contact lenses. Contact lenses should be removed before use and for at least 30 minutes after administration of MIEBO
    Instruct patients to instill one drop of MIEBO into each eye four times daily
    The safety and efficacy in pediatric patients below the age of 18 have not been established
    The most common ocular adverse reaction was blurred vision (1% to 3% of patients reported blurred vision and conjunctival redness)
    You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1800FDA10
    Sign Improvement and Symptom Relief
    Sign Improvement
    (Total Corneal Fluorescein Staining)
    Symptoms Relief
    (Eye Dryness)
    Sign Improvement
    (Central Corneal Fluorescein Staining)
    MEIBO
    Saline(control)
    2x
    Improvement vs Control in total CFS at day 57
    Pooled analysis (above): Mean baseline tCFS = 6.9 for MIEBO and saline (control).

    tCFS grading scale: 015 (0-3 in each of 5 areas). Across GOBI and MOJAVE, 614 patients received MIEBO and 603 patients received control with 591 and 575, respectively, assessed on Day 57.2-4

    INDIVIDUAL STUDY DATA1-3

    GOBI: Mean (SD) CFB -2.0 (2.6) for MIEBO(n = 289) vs -1.0 (2.7) for control (n = 279) (P < 0.001) at Day 57.

    MOJAVE: Mean (SD) CFB -2.3(2.8) for MIEBO (n = 302) vs -1.1(2.9) for control (n = 296) (P < 0.001) at Day 57.

    CFB, change from baseline; CFS, corneal fluorescein staining.
    1.5x
    Improvement vs Control in eye dryness at day 57
    Pooled analysis (above): Mean baseline eye dryness score = 65.6 for MIEBO, 65.5 for saline (control).

    Eye dryness Visual Analog Scale VAS: 0-100 (0 = no discomfort, 100 = maximal discomfort). Across GOBI and MOJAVE, 614 patients received MIEBO and 603 patients received control with 591 and 575, respectively, assessed on Day 57.24

    INDIVIDUAL STUDY DATA1-3

    GOBI: Mean (SD) CFB -27.4 (27.9) for MIEBO (n = 289) vs -19.7 (26.7) for saline (n = 279) (P < 0.001) at Day 57.

    MOJAVE: Mean (SD) CFB -29.5 (28.6) for MIEBO (n = 302) vs -19.0 (27.2) for saline (n = 296) (P < 0.001) at Day 57.
    4x
    Improvement vs Control in central CFS at day 57
    Pooled analysis (above): Mean baseline cCFS = 1.1 for MIEBO and saline (control).

    cCFS grading scale: : 0-3. Across GOBI and MOJAVE, 614 patients received MIEBO and 603 patients received control with 591 and 575, respectively, assessed on Day 57.2-4

    INDIVIDUAL STUDY DATA2-4

    GOBI: Mean (SD) CFB -0.4 (0.8) for MIEBO (n = 289) vs -0.1 (0.9) for saline (n = 279) (P < 0.001) at Day 57.

    MOJAVE: Mean (SD) CFB -0.4 (0.8) for MIEBO (n = 302) vs -0.1 (0.9) for saline (n = 296) (P < 0.001) at Day 57.
    Study design
    The first and only approved Rx eye drop that required all patients in pivotal studies to have clinical signs of MGD at enrollment
    Two 57-day, multicenter, double-masked, saline-controlled studies GOBI and MOJAVE were conducted in adults 18 years old with a self-reported history of DED in both eyes. Primary outcomes were change from baseline in tCFS and change from baseline in eye dryness score (Visual Analog Scale) at Day 57. Day 15 was the earliest time point at which signs and symptoms were evaluated in the trials. Day 57 was the last.1-3
    Objective
    Key Inclusion Criteria
    Base Characteristics
    Study Outcomes
    Efficacy and safety were established in 2 large clinical trials that enrolled 1200 patients2,3
    GOBI and MOJAVE
    Two 57-day
    Multicenter
    Double-masked
    Saline-controlled studies
    Adults >= 18 years old with self-reported history of DED in both eyes2,3
    MGD defined as a total MGD score >=3
    Based on secretion of 5 central glands on lower eyelid (each scored 0-3)
    0 = normal
    1 = thick/yellow, whitish, particular
    2 = paste
    3 = none/occluded
    Depending on study and treatment arm
    Mean total MGD score: 7.6
    Mean tCFS: 6.9
    Mean TFBUT (sec): 3.2
    Mean OSDI score: 54.6
    Eye dryness VAS score: 65.6
    *GOBI MIEBO vs control SD, respectively): Mean total MGD score, 7.4 3.1 vs 7.7 3.2; mean tCFS, 6.7 1.8 vs 6.7 1.9; mean TFBUT (sec), 3.2 0.8 vs 3.3 0.8; mean OSDI score, 53.9 17.6 vs 54.4 17; eye dryness VAS score, 66.5 19.1 vs 66.8 18.7. MOJAVE MIEBO vs control SD, respectively): Mean total MGD score, 7.9 3.5 vs 8.1 3.5; mean tCFS, 7.0 2.0 vs 7.1 2.1; mean TFBUT (sec), 3.2 0.9 vs 3.1 0.9; mean OSDI score, 55.2 17.4 vs 55.8 17.2; eye dryness VAS score, 64.7 19.5 vs 64.3 19.8.2,3
    OSDI, Ocular Surface Disease Index; QID, 4 times a day; TFBUT, tear film break-up time.
    INDICATION
    MIEBO™ (perfluorohexyloctane ophthalmic solution) is a semifluorinated alkane indicated for the treatment of the signs and symptoms of dry eye disease.
    IMPORTANT SAFETY INFORMATION
    MIEBO should not be administered while wearing contact lenses. Contact lenses should be removed before use and for at least 30 minutes after administration of MIEBO
    Instruct patients to instill one drop of MIEBO into each eye four times daily
    The safety and efficacy in pediatric patients below the age of 18 have not been established
    The most common ocular adverse reaction was blurred vision (1% to 3% of patients reported blurred vision and conjunctival redness)
    You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1800FDA10